Compound ID | 1335
Class: COX-2 inhibitor
| Spectrum of activity: | Gram-positive |
| Institute where first reported: | Pfizer; Upjohn |
| Year first mentioned: | 1999 |
| Highest development stage: | Approved by FDA in 1998 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/2662 |
| Citation: | https://academic.oup.com/jac/article-abstract/74/12/3462/5581809?redirectedFrom=fulltext |